Modality
siRNA
MOA
FXIai
Target
MET
Pathway
Innate Imm
FSGSRBADPKD
Development Pipeline
Preclinical
~May 2021
→ ~Aug 2022
Phase 1
Nov 2022
→ Jul 2026
Phase 1Current
NCT08310091
1,531 pts·RB
2022-11→2026-07·Recruiting
1,531 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-075mo agoFast Track· RB
2026-07-284mo awayInterim· RB
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1
Recruit…
Catalysts
Fast Track
2025-11-07 · 5mo ago
RB
Interim
2026-07-28 · 4mo away
RB
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08310091 | Phase 1 | RB | Recruiting | 1531 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Pexanesiran | United Therapeutics | Phase 1 | BCMA |